GT Biopharma Inc (GTBP): GT Biopharma a new buy at H.C. Wainwrigh...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

GT Biopharma Inc (GTBP)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	224
Posts	31832
Boards Moderated	4
Alias Born	10/10/2005

Re: OilRush post# 18573

Wednesday, 05/26/2021 11:53:58 AM

Wednesday, May 26, 2021 11:53:58 AM

GT Biopharma a new buy at H.C. Wainwright

The platform used by GT Biopharma (NASDAQ:GTBP) “constitutes a precision medicine assembly line” notes H.C. Wainwright analyst Robert Burns in initiating the coverage on the stock with a buy rating. The price target of $25.00 per share indicates an upside of ~74.1%.

The company’s candidates based on its proprietary NK cell engager (TriKE) protein biologic technology platform have "the potential to overcome certain limitations of CAR-T therapy, emerging cell-based immunotherapy approaches and other antibody therapies,” the analyst wrote.

In April, GT Biopharma appointed Gregory Berk a 30 year veteran in oncology drug development as its new chief medical officer.
All share price moves are calculated based on the market close unless otherwise stated.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent GTBP News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/19/2023 03:56:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:55:28 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:29:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:26:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 01:00:11 PM

More GTBP News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow